Cover Image
市場調查報告書

肺結核病:開發平台評估

Pulmonary Tuberculosis - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 253667
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
肺結核病:開發平台評估 Pulmonary Tuberculosis - Pipeline Review, H2 2014
出版日期: 2014年09月22日 內容資訊: 英文 63 Pages
簡介

肺結核是由結核菌引起的感染病(發炎),會造成包含疲勞、多汗、喀血、長期體溫過高等發燒症狀。年齡及HIV/AIDS,糖尿病,化療等的癌症治療,營養失調等是致病因子,有抗結核藥等治療方法。

本報告網羅全球肺結核病治療藥開發平台資訊,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的商品評估等。

目錄

簡介

  • 分析範圍

肺結核病概要

治療藥的開發

  • 肺結核病開發中產品:概要
  • 肺結核病開發中產品:比較分析

肺結核病:正在開發的治療藥:各企業

肺結核病:正在開發的治療藥:大學·研究機關別

肺結核病:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

肺結核病:開發中的產品:各企業

肺結核病:開發中的產品:大學·研究機關別

肺結核病:治療藥的開發企業

  • Johnson & Johnson
  • Sequella, Inc.
  • AstraZeneca PLC
  • Microbion Corporation

肺結核病:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • bedaquiline fumarate
  • SQ-109
  • sutezolid
  • AZD-5847
  • PA-824
  • rBCG30疫苗
  • SQ-609
  • r30疫苗
  • methionine sulfoximine
  • Live Recombinant Booster Vaccine
  • 肺炎, 慢性阻塞性肺病, 囊狀纖維化症, 肺結核病小分子
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5486IDB

Summary

Global Markets Direct's, 'Pulmonary Tuberculosis - Pipeline Review, H2 2014', provides an overview of the Pulmonary Tuberculosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Tuberculosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Tuberculosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Tuberculosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pulmonary Tuberculosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pulmonary Tuberculosis Overview
  • Therapeutics Development
    • Pipeline Products for Pulmonary Tuberculosis - Overview
    • Pipeline Products for Pulmonary Tuberculosis - Comparative Analysis
  • Pulmonary Tuberculosis - Therapeutics under Development by Companies
  • Pulmonary Tuberculosis - Therapeutics under Investigation by Universities/Institutes
  • Pulmonary Tuberculosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pulmonary Tuberculosis - Products under Development by Companies
  • Pulmonary Tuberculosis - Products under Investigation by Universities/Institutes
  • Pulmonary Tuberculosis - Companies Involved in Therapeutics Development
    • Johnson & Johnson
    • Sequella, Inc.
    • AstraZeneca PLC
    • Microbion Corporation
  • Pulmonary Tuberculosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bedaquiline fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sutezolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • posizolid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pretomanid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pulmonary tuberculosis + leprosy vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SQ-609 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • r30 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methionine sulfoximine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pulmonary Tuberculosis - Recent Pipeline Updates
  • Pulmonary Tuberculosis - Dormant Projects
  • Pulmonary Tuberculosis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis
      • Jul 26, 2013: Otsuka Receives Opinion from CHMP on Delamanid
      • Jul 02, 2012: Janssen Submits New Drug Application To FDA For Bedaquiline For Multi-Drug Resistant Tuberculosis Treatment
      • Oct 18, 2010: Sequella Receives International Support For Phase II Clinical Trials Of SQ109 For Treatment Of Adult Pulmonary Tuberculosis
      • Oct 18, 2005: The Global Alliance for TB Drug Development Announces Phase II Trials To Study Potential Of Moxifloxacin To Shorten TB Treatment Partners Commit To Affordable Pricing For Patients In The Developing World
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pulmonary Tuberculosis, H2 2014
  • Number of Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Pulmonary Tuberculosis - Pipeline by Johnson & Johnson, H2 2014
  • Pulmonary Tuberculosis - Pipeline by Sequella, Inc., H2 2014
  • Pulmonary Tuberculosis - Pipeline by AstraZeneca PLC, H2 2014
  • Pulmonary Tuberculosis - Pipeline by Microbion Corporation, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Pulmonary Tuberculosis Therapeutics - Recent Pipeline Updates, H2 2014
  • Pulmonary Tuberculosis - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Pulmonary Tuberculosis, H2 2014
  • Number of Products under Development for Pulmonary Tuberculosis - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top